Cencora, Inc. $COR Shares Purchased by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC raised its holdings in Cencora, Inc. (NYSE:COR) by 20.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,000 shares of the company’s stock after acquiring an additional 3,000 shares during the quarter. Cencora comprises approximately 3.3% of Sivik Global Healthcare LLC’s holdings, making the stock its 12th largest position. Sivik Global Healthcare LLC’s holdings in Cencora were worth $5,404,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of COR. Elevation Wealth Partners LLC lifted its stake in shares of Cencora by 506.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 97 shares of the company’s stock valued at $27,000 after purchasing an additional 81 shares during the last quarter. Bell Investment Advisors Inc bought a new position in Cencora during the second quarter valued at about $28,000. Caitlin John LLC bought a new position in Cencora during the second quarter valued at about $28,000. Cassaday & Co Wealth Management LLC acquired a new position in shares of Cencora during the 1st quarter valued at about $35,000. Finally, Western Wealth Management LLC bought a new position in shares of Cencora in the 1st quarter valued at approximately $49,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of Cencora stock traded up $5.34 during trading on Tuesday, reaching $330.40. The company’s stock had a trading volume of 394,263 shares, compared to its average volume of 1,471,057. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93. The business’s fifty day moving average price is $318.82 and its 200-day moving average price is $302.72. The firm has a market cap of $63.05 billion, a price-to-earnings ratio of 24.54, a price-to-earnings-growth ratio of 1.66 and a beta of 0.58. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The business had revenue of $84.75 billion during the quarter, compared to analysts’ expectations of $84.31 billion. During the same quarter in the previous year, the firm earned $4.00 EPS. The firm’s revenue was up 5.1% compared to the same quarter last year. As a group, equities research analysts predict that Cencora, Inc. will post 17.87 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Friday, August 14th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, August 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is 17.83%.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on COR. Royal Bank Of Canada restated a “sector perform” rating and issued a $330.00 target price on shares of Cencora in a report on Tuesday, September 8th. Robert W. Baird increased their price target on Cencora from $370.00 to $373.00 and gave the company an “outperform” rating in a report on Monday. Bank of America lifted their price target on shares of Cencora from $285.00 to $310.00 in a research report on Tuesday, July 21st. Wells Fargo & Company lifted their price target on shares of Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Finally, Argus reduced their price objective on shares of Cencora to $340.00 and set a “buy” rating for the company in a research note on Tuesday, June 23rd. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $365.69.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. This represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.38% of the company’s stock.

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.